INFO & CONTACTS:  +39 02 2390 1

A phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of Ifinatamab Deruxtecan (I-DXD) in subjects With recurrent or metastatic solid tumors

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Damian Silvia

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: ifinatamab deruxtecan (I-DXd)

Pathologies: Advanced Solid Tumours

ClinicalTrials.gov: Read the details about clinical trials

This is a global, multicenter, pan-tumor, open-label, single-treatment arm, phase 1b/2 study of I-DXd in subjects with recurrent or metastatic solid tumors previously treated with 1 or more systemic therapies for the selected tumor indication.

The aim of this study is to evaluate the efficacy and safety of I-DXd administered in monotherapy.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe